Optimal duration of adjuvant targeted-immunotherapy in patients with initially unresectable hepatocellular carcinoma with portal vein tumor thrombus following successful conversion therapy. - Wang L; Feng JK; Zhou B; Liu ZH; Gong L; Yan ML; Zhao HT; Jiang YB; Shi J; Guo WX; Yuan Y; Lu CD; et al. (The oncologist, 2026)